M. Doyle

Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies

S. Zhuang, F. Clow, Steven Sun, 2015, Annals of the New York Academy of Sciences.

Real-world data confirming the efficacy and safety of decitabine in acute myeloid leukaemia – results from a retrospective Belgian registry study

P. Chevalier, D. Dierickx, I. Vande broek, 2019, Acta clinica Belgica.

Decitabine improves response rate and prolongs progression‐free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO‐016 trial

H. Kantarjian, F. Ravandi, A. Oriol, 2018, American journal of hematology.

Chronic lymphocytic leukemia-associated membranous glomerulopathy: remission with fludarabine.

F. Cortese, G. Rutecki, J. Asfoura, 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL

V. Leblond, C. Dartigeas, C. Tapprich, 2022, Clinical Hematology International.

A phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients (pts) with newly diagnosed supratentorial high grade malignant glioma (MG) who have undergone surgery with carmustine (BCNU) wafer insertion

L. Stribinskiene, T. Vitaz, P. New, 2005 .

Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma

A. Nooka, R. Verona, M. Qi, 2023, Cancer.